CG10504 antibody, CT29478 antibody, DmILK antibody, Dmel\\CG10504 antibody, ILK antibody, ilk antibody, l(3)78Ca antibody, p59 antibody, AA511515 antibody, ESTM24 antibody, zgc:65842 antibody, ILK-1 antibody, ILK-2 antibody, P59 antibody, p59ILK antibody, Integrin linked kinase antibody, integrin linked kinase antibody, integrin linked kinase S homeolog antibody, integrin-linked protein kinase antibody, integrin-linked kinase antibody, Ilk antibody, ILK antibody, ilk.S antibody, CpipJ_CPIJ016644 antibody, Bm1_20815 antibody, Tsp_07213 antibody, Tsp_07224 antibody, Tsp_15354 antibody, ilk antibody
Transduction of extracellular matrix signals through integrins influences intracellular and extracellular functions, and appears to require interaction of integrin cytoplasmic domains with cellular proteins. Integrin-linked kinase (ILK) is an ankyrin repeat containing 51 kDa receptor-proximate serine-threonine kinase (1), with a reported migration rate of 59K. This 451 amino acid protein interacts with the cytoplasmic domain of the beta-1 integrin subunit and contains sequence motifs found in pleckstrin homology domains capable of interacting with phosphoinositide lipids. ILK is an upstream regulator of Pi(3)K dependant activation of protein kinase B (PKB/AKT) and inhibition of glycogen synthase kinase 3 (GSK-3). ILK2 expression is associated with mediation of cell architecture, adhesion to integrin substrates and anchorage-dependent growth in epithelial cells. ILK2 is overexpressed in some highly invasive tumor cell lines.